Drug Trial Radar · NCT05555251
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Jul 28, 2022
Primary completion
Feb 7, 2024
Study completion Feb 7, 2024
Sponsor
- Lead sponsor
- BioInvent International ABIndustry
- Sponsor type
- Industry
- First posted
- Sep 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HER2+ breast and gastric cancer patients' survival is significantly improved by trastuzumab alone or in combination with chemotherapy. However, many patients remain uncured and develop resistance to trastuzumab resulting in relapse or progression of the disease. BI-1607, a human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) targets CD32b (Fc Gamma Receptor IIB), it is intended to enhance the efficacy and overcome resistance to existing cancer treatments such as trastuzumab. This is a Phase 1/2a, first-in-human, open-label, multicenter, dose-escalation, consecutive-cohort study of BI-1607 in combination with trastuzumab in subjects with HER2+ advanced solid tumors whose tumor has progressed after standard therapy.
Conditions
- HER2-positive Breast Cancer
- HER2-positive Gastric Cancer
- HER2-positive Metastatic Breast Cancer
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastric Adenocarcinoma
Interventions
BI-1607Drug
administered at different doses in Phase I by intravenous infusions every 3 weeks.
BI-1607Drug
administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.
TrastuzumabDrug
administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of the safety and tolerability profile of BI-1607 in combination with trastuzumabTime frame: End of treatment visit or 30 days after last dose of study drug.
- Identify Dose limiting toxicities, determine the maximum tolerate dose of BI-1607 and propose a recommended Phase 2 dose (RP2D) for evaluation of BI-1607 in combination with trastuzumab.Time frame: 22 days
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Evang. Kliniken Essen-Mitte
Essen, Germany
Krankenhaus Nordwest
Frankfurt, Germany
Hospital Vall d'Hebron
Barcelona, Spain
Complejo hospitalario Ruber Juan Bravo
Madrid, Spain
Churchill Hospital
Oxford, United Kingdom
Southampton General Hospital
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.